



## Clearbridge Utilises Bank Facilities for Healthcare-related Acquisitions in its EBITDA-focused Strategy

- *Bank facilities of approximately S\$5.3 million have been used for three healthcare-related acquisitions till date*
- *The three high-growth acquisitions have been accretive to the Group's financial performance since completion*
- *Reflects ongoing efforts to optimise capital structure and provide financial flexibility to pursue its EBITDA-focused strategy*

**SINGAPORE, 15 April 2019** – Integrated healthcare company Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (“明策集團”), is pleased to update that it has utilised approximately S\$5.3 million out of the Group’s S\$6.7 million bank facilities for the following healthcare-related acquisitions:

- Philippines-based healthcare services provider, Clearbridge Medical (Philippines), Inc. (formerly known as Marzan Health Care Inc.);
- Indonesia-based renal care services provider, PT Tirta Medika Jaya; and
- Singapore-based medical and aesthetic services provider, Medic Surgical Private Limited and Medic Laser Private Limited.

Since the completion of these acquisitions by Clearbridge, the business activities of the three healthcare-related providers in Asia have grown progressively.

Notably, these three healthcare-related companies have become key components of the Group’s financial performance, accounting for approximately 84% of the Group’s revenue in FY2018.

Since its IPO in December 2017, Clearbridge has embarked on an EBITDA-focused expansion strategy that has significantly expanded its business presence in Southeast Asia, serving multiple segments of the healthcare industry.

**Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge,** said, *“One of our key goals is to build a strong, flexible balance sheet that will significantly enhance our execution ability to enhance long-term shareholder value.”*

*We appreciate the ongoing support and confidence of the financial institutions as we move forward in our EBITDA-focused strategy in Asia through organic growth and acquisitions.*

*With the Group’s revenue surging more than 20-fold in FY2018, this bears testament to our strategy and business model in the burgeoning healthcare markets within Asia.”*



– END –

**Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.**

**Media & Investor Contacts:**



Mr. Alex TAN  
Mobile: +65 9451 5252  
Email: [alex.tan@8prasia.com](mailto:alex.tan@8prasia.com)

**About Clearbridge Health Limited**

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies.

Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. It is executing the above strategies by way of primary healthcare and healthcare systems that reside in nexus of high demand.

For more information, please visit us at [www.clearbridgehealth.com](http://www.clearbridgehealth.com).

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").*

*The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*